A company modified a device that has FDA-established performance standards for the device and the modification already in place. Which FDA filing type should the company submit?

A company modified a device that has FDA-established performance standards for the device and the modification already in place. Which FDA filing type should the company submit?

• A. 510(k) full
• B. Abbreviated 510(k)
• C. PMA
• D. De Novo

Answer: (B)

When a device already has FDA-established performance standards and you’re making a modification to it, the most efficient way to gain clearance is to rely on consensus standards through an Abbreviated 510(k). This filing pathway lets you demonstrate substantial equivalence by showing the modified device meets recognized standards that define its performance. Because the standards provide objective criteria, you can focus on testing and documentation that confirm the device aligns with those criteria rather than collecting a broad range of new data. If you didn’t have standards to lean on, a full 510(k) would be more typical, requiring more evidence to prove substantial equivalence. PMA is for high-risk devices needing extensive clinical data, and De Novo is for entirely novel devices without a predicate. Here, the presence of FDA-established performance standards makes the Abbreviated 510(k) the appropriate, streamlined route for the modification.

When a device already has FDA-established performance standards and you’re making a modification to it, the most efficient way to gain clearance is to rely on consensus standards through an Abbreviated 510(k). This filing pathway lets you demonstrate substantial equivalence by showing the modified device meets recognized standards that define its performance. Because the standards provide objective criteria, you can focus on testing and documentation that confirm the device aligns with those criteria rather than collecting a broad range of new data.

If you didn’t have standards to lean on, a full 510(k) would be more typical, requiring more evidence to prove substantial equivalence. PMA is for high-risk devices needing extensive clinical data, and De Novo is for entirely novel devices without a predicate. Here, the presence of FDA-established performance standards makes the Abbreviated 510(k) the appropriate, streamlined route for the modification.